[Sulacillin (a combination of ampicillin and sulbactam)--a new combined drug form for treatment of bacterial infections].

Abstract

The results of the cooperated clinical trial of sulacillin, a formulation including sodium ampicillin and sulbactam (2:1), are presented. The trial was carried out in different hospitals of Moscow and Smolensk. Rapid development of the favourable time course and recovery were stated in 93.7 per cent of the cases with upper and lower respiratory tract infections, urinary and biliferous tract infections, infections of the skin and soft tissues, gynecological infections and severe suppurative complications after surgical operations. Sulacillin is useful in the empirical therapy of purulent inflammatory diseases before the pathogen isolation and identification.

• Authors: N S Bogomolova, O N Belova, M M Vasil'ev, Iu A Novikova, G F Pankova, T S Perepanova, V I Sokolova, L S Strachunskiĭ, I N Shandurenko, V P Pozdniakova
• Journal: Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] (Antibiot Khimioter) Vol. 40 Issue 6 Pg. 43-8 (Jun 1995) ISSN: 0235-2990 [Print] Russia (Federation)
• Vernacular Title: Sulatsillin (sochetanie ampitsillina s sul'baktamom)--novaia kombinirovannaia lekarstvennaia forma dlia lecheniia bakterial'nykh infektsiĭ.
• PMID: 8593095 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article, Multicenter Study)

Chemical References

• Anti-Bacterial Agents
• Drug Combinations
• Ampicillin
• sulacillin
• Sulbactam

Topics

• Ampicillin (therapeutic use)
• Anti-Bacterial Agents (therapeutic use)
• Bacterial Infections (drug therapy)
• Child
• Drug Combinations
• Humans
• Russia
• Sulbactam (therapeutic use)
• Treatment Outcome